9/1026 sources · 12 publishersUpdated Oct 30, 19:14 UTC
AbbVie reports Q3 2026 results, raises FY‑2026 adjusted EPS guidance and dividend
AbbVie announced third‑quarter 2026 results on Oct. 30, showing net revenue of $17.404 billion, up 10.3% YoY. Adjusted diluted EPS was $3.82 and the company lifted its full‑year 2026 adjusted EPS guidance to $13.95‑$13.99. It also completed the acquisition of Apogee Therapeutics and increased the quarterly dividend by 5.2% for 2027.
Why it matters
The higher guidance and dividend increase signal stronger cash flow, which may support a higher valuation for ABBV (the company expects the raised EPS range, per the press release). The acquisition of Apogee expands AbbVie’s immunology pipeline, potentially adding future revenue streams.
Key facts
- 1Third‑quarter net revenues were $17.404 billion, an increase of 10.3% on a reported basis. prnewswire.com
- 2Adjusted diluted EPS for the quarter was $3.82, an increase of over 100.0% versus the prior year. prnewswire.com
- 3The company raised its 2026 adjusted diluted EPS guidance range to $13.95‑$13.99, up from $13.76‑$13.96. prnewswire.com
- 4AbbVie announced a 5.2% increase to the quarterly dividend, payable in February 2027. prnewswire.com
- 5AbbVie completed the acquisition of Apogee Therapeutics. prnewswire.com
- 6Global Skyrizi net revenues were $5.776 billion, up 22.7% on a reported basis. prnewswire.com
Summary written by AlphAI AI Desk from 20 of 26 sources. Not investment advice. Figures are as stated by the linked sources.